Vitiligo and melanoma‐associated hypopigmentation (MAH):shared and discriminative features

Background: It is unclear if differences between melanoma‐associated hypopigmentation (MAH) and classical vitiligo exist.

[1]  A. Hauschild,et al.  Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low‐dose interferon alpha , 2007, International journal of cancer.

[2]  James J. Nordlund,et al.  The Pigmentary System: Physiology and Pathophysiology: Second Edition , 2007 .

[3]  U. Reinhold,et al.  Incidence of antiretinal antibodies in melanoma: screening of 77 serum samples from 51 patients with American Joint Committee on Cancer stage I-IV. , 2005, The British journal of dermatology.

[4]  E. Bröcker,et al.  Narrow‐band UVB311 nm vs. broad‐band UVB therapy in combination with topical calcipotriol vs. placebo in vitiligo , 2005, International journal of dermatology.

[5]  J. Becker,et al.  Hypopigmentary Skin Disorders Current Treatment Options and Future Directions , 2004, Drugs.

[6]  B. Moncada,et al.  A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. , 2003, Archives of Dermatology.

[7]  J. Becker,et al.  Differential expression of inhibitory or activating CD94/NKG2 subtypes on MART-1-reactive T cells in vitiligo versus melanoma: a case report. , 2002, The Journal of investigative dermatology.

[8]  C. R. Müller.  Populationsgenetische Parameter der Gewebemerkmale der deutschen Bevölkerung und ihre Anwendung bei der Suche nach nicht-verwandten Blutstammzellspendern , 2002 .

[9]  J. Bosq,et al.  Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo. , 2001, The Journal of investigative dermatology.

[10]  A. Necker,et al.  Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. , 2001, The Journal of investigative dermatology.

[11]  G. Fishman,et al.  Retinal findings in melanoma-associated retinopathy. , 2001, American journal of ophthalmology.

[12]  W. Westerhof,et al.  Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. , 2000, Journal of the American Academy of Dermatology.

[13]  J. Becker,et al.  Accumulation of identical T cells in melanoma and vitiligo-like leukoderma. , 1999, The Journal of investigative dermatology.

[14]  Y. Hsin-Su.  The Pigmentary System: Physiology and Pathophysiology , 1999 .

[15]  Watson,et al.  Autoantibodies to tyrosinase‐related protein‐1 detected in the sera of vitiligo patients using a quantitative radiobinding assay , 1998, The British journal of dermatology.

[16]  G. Ogg,et al.  High Frequency of Skin-homing Melanocyte-specific Cytotoxic T Lymphocytes in Autoimmune Vitiligo , 1998, The Journal of experimental medicine.

[17]  W. Jochum,et al.  T cells involved in psoriasis vulgaris belong to the Th1 subset. , 1994, The Journal of investigative dermatology.

[18]  H. Nakagawa,et al.  Difference in clinical features and HLA antigens between familial and non‐familial vitiligo of non‐segmental type , 1993, The British journal of dermatology.

[19]  A. Kopf,et al.  Prognostic significance of hypopigmentation in malignant melanoma. , 1987, Archives of dermatology.

[20]  M. Mihm,et al.  Malignant melanoma and vitiligo-like leukoderma: an electron microscopic study. , 1983, Journal of the American Academy of Dermatology.

[21]  J. Kirkwood,et al.  Vitiligo in patients with metastatic melanoma: a good prognostic sign. , 1983, Journal of the American Academy of Dermatology.

[22]  E. Bröcker,et al.  Occlusive treatment enhances efficacy of tacrolimus 0.1% ointment in adult patients with vitiligo: results of a placebo-controlled 12-month prospective study. , 2008, Acta dermato-venereologica.

[23]  S. Rodriguez-Cuevas,et al.  Prognostic significance of cutaneous depigmentation in Mexican patients with malignant melanoma. , 1998, Archives of medical research.

[24]  S. Rosenberg,et al.  Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[25]  K. Schallreuter,et al.  Total serum immunoglobulins and atopic symptoms in patients with vitiligo. , 1994, Dermatology.

[26]  P. Kühnl,et al.  Histocompatibility antigens in vitiligo: Hamburg study on 102 patients from northern Germany. , 1993, Dermatology.

[27]  K. Schallreuter,et al.  Vitiligo and cutaneous melanoma. A case study. , 1991, Dermatologica.

[28]  A. Numé,et al.  Prevalence of atopy in vitiligo. A preliminary report. , 1991, Dermatologica.